Literature DB >> 2783922

Adjuvant effects of trehalose dimycolate on the antibody response to type III pneumococcal polysaccharide.

P J Baker1, M B Fauntleroy, P W Stashak, J R Hiernaux, J L Cantrell, J A Rudbach.   

Abstract

Treatment with trehalose dimycolate (TDM) increases the magnitude of the immunoglobulin M (IgM) antibody response of mice to type III pneumococcal polysaccharide (SSS-III). Such enhancement is demonstrable over a wide range of immunizing doses and does not require thymus-derived (T) cells to be elicited. Although young adult mice immunized with SSS-III do not usually make anti-SSS-III antibodies of the IgG1 and IgG3 classes, antibodies of one or both isotypes were produced after immunization and treatment with TDM and/or monophosphoryl lipid A (MPL); the additive nature of the effect produced by both TDM and MPL suggests that the two immunomodulators act by different mechanisms. TDM and MPL have different effects on the induction and expression of low-dose immunological paralysis, a form of unresponsiveness known to be mediated by suppressor T cells. The relevance of these findings to the modes of action of TDM and MPL is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783922      PMCID: PMC313198          DOI: 10.1128/iai.57.3.912-917.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Kinetics of the antibody response to type III pneumococcal polysaccharide. I. Evidence that suppressor cells function by inhibiting the recruitment and proliferation of antibody-producing cells.

Authors:  J M Jones; D F Amsbaugh; P W Stashak; B Prescott; P J Baker; D W Alling
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

2.  Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. 3. Studies on the average avidity of the antibody produced by specific plaque-forming cells.

Authors:  P J Baker; B Prescott; P W Stashak; D F Amsbaugh
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

3.  Application of transformations to normalize the distribution of plaque-forming cells.

Authors:  C F Gottlieb
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

4.  Adjuvant effect of cord factor, a mycobacterial lipid.

Authors:  R Saito; A Tanaka; K Sugiyama; I Azuma; Y Yamamura
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

5.  Direct evidence for the involvement of T suppressor cells in the expression of low-dose paralysis to type III pneumococcal polysaccharide.

Authors:  P J Baker; D F Amsbaugh; P W Stashak; G Caldes; B Prescott
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

6.  Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells.

Authors:  P J Baker; D F Amsbaugh; P W Stashak; G Caldes; B Prescott
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

7.  Immune response to sheep red blood cells in mice pretreated with mycobacterial fractions.

Authors:  A Bekierkunst; E Yarkoni; I Flechner; S Morecki; E Vilkas; E Lederer
Journal:  Infect Immun       Date:  1971-09       Impact factor: 3.441

8.  Proliferative responses of central and peripheral rat lymphocytes elicited by cord factor (trehalose 6,6'-dimycolate).

Authors:  F Kierszenbaum; D R Walz
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

9.  Synthesis of two classes of antibody, gammaM and gammaG or gammaM and gammaA, by identical cells. Amplification of the antibody response to pneumococcal polysaccharide type III.

Authors:  V J Pasanen; R Asofsky; P J Baker
Journal:  J Exp Med       Date:  1979-05-01       Impact factor: 14.307

10.  Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. II. Relationship between IgM immunoglobulin levels and the ability to give an IgM antibody response.

Authors:  D F Amsbaugh; C T Hansen; B Prescott; P W Stashak; R Asofsky; P J Baker
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes.

Authors:  P J Baker
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

3.  Immunomodulatory activity of monophosphoryl lipid A in C3H/HeJ and C3H/HeSnJ mice.

Authors:  J R Hiernaux; P W Stashak; J L Cantrell; J A Rudbach; P J Baker
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

Review 4.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses.

Authors:  James P Phipps; Karen M Haas
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

6.  Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens.

Authors:  D J Rawlings; D C Kaslow
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

Review 7.  Sweeten PAMPs: Role of Sugar Complexed PAMPs in Innate Immunity and Vaccine Biology.

Authors:  Ranjeet Singh Mahla; Madhava C Reddy; D Vijaya Raghava Prasad; Himanshu Kumar
Journal:  Front Immunol       Date:  2013-09-02       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.